



## **Ventripoint Announces Sponsorship for the 2021 Canadian Society of Echocardiography Weekend Conference**

**Toronto, Ontario – The Newswire – April 15, 2021** - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is pleased to announce its sponsorship of the 2021 Canadian Society of Echocardiography (CSE) Virtual Echo Weekend Conference to be held this weekend on April 17-18, 2021.

The CSE strives to promote high quality echocardiographic services across Canada. The CSE Virtual Echo Weekend is a yearly conference which educates cardiologists, internists, sonographers, and trainees from across the country on how novel and evolving echocardiography techniques can be applied to the clinical practice.

For the 2021 Annual CSE Virtual Weekend is a multi-day event and will include a scientific abstract competition from trainees and early career faculty across Canada, as well as an exploration of new developments in clinical applications of echocardiography technology.

Ventripoint will be part of the virtual exhibit hall and will be showcasing its current and future products to the expected 3,000 attendees from across North America and international partners.

Ventripoint is dedicated to developing products that give accurate and reliable measurements of cardiac function at a reduced cost to the healthcare system. Ventripoint's involvement in the CSE Virtual Echo Weekend Conference demonstrates the commitment to supporting effective clinical assessment and diagnosis through education and promotion.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
[gadams@venripoint.com](mailto:gadams@venripoint.com)  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.